Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.
Cuorvo LV, Verderio P, Ciniselli CM, Girlando S, Decarli N, Leonardi E, Ferro A, Caldara A, Triolo R, Eccher C, Cantaloni C, Mauri F, Seckl M, Volante M, Buttitta F, Marchetti A, Silvia Q, Galligioni E, Palma PD, Barbareschi M. Cuorvo LV, et al. Among authors: cantaloni c. Virchows Arch. 2014 Jan;464(1):85-93. doi: 10.1007/s00428-013-1500-7. Virchows Arch. 2014. PMID: 24233241
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.
Barbareschi M, Cuorvo LV, Girlando S, Bragantini E, Eccher C, Leonardi E, Ferro A, Caldara A, Triolo R, Cantaloni C, Decarli N, Galligioni E, Dalla Palma P. Barbareschi M, et al. Among authors: cantaloni c. Virchows Arch. 2012 Aug;461(2):129-39. doi: 10.1007/s00428-012-1267-2. Epub 2012 Jun 29. Virchows Arch. 2012. PMID: 22744290
In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases.
Giuliani S, Ciniselli CM, Leonardi E, Polla E, Decarli N, Luchini C, Cantaloni C, Gasperetti F, Cazzolli D, Berlanda G, Bernardi D, Pellegrini M, Triolo R, Ferro A, Verderio P, Barbareschi M. Giuliani S, et al. Among authors: cantaloni c. Virchows Arch. 2016 Jul;469(1):45-50. doi: 10.1007/s00428-016-1940-y. Epub 2016 Apr 21. Virchows Arch. 2016. PMID: 27097809
Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.
Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, Gasperetti F, Berlanda G, Dalla Palma P, Barbareschi M. Fasanella S, et al. Among authors: cantaloni c. Diagn Pathol. 2011 Mar 30;6 Suppl 1(Suppl 1):S7. doi: 10.1186/1746-1596-6-S1-S7. Diagn Pathol. 2011. PMID: 21489202 Free PMC article.
Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system.
Cantaloni C, Tonini R E, Eccher C, Morelli L, Leonardi E, Bragantini E, Aldovini D, Fasanella S, Ferro A, Cazzolli D, Berlanda G, Dalla Palma P, Barbareschi M. Cantaloni C, et al. Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):306-12. doi: 10.1097/PAI.0b013e318205b03a. Appl Immunohistochem Mol Morphol. 2011. PMID: 21293256
miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas.
Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E, Fasanella S, Cuorvo LV, Palma PD, Rossi G, Papotti M, Pelosi G, Graziano P, Cavazza A, Denti MA, Barbareschi M. Del Vescovo V, et al. Among authors: cantaloni c. Am J Surg Pathol. 2011 Feb;35(2):268-75. doi: 10.1097/PAS.0b013e3182068171. Am J Surg Pathol. 2011. PMID: 21263248
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.
Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Dalla Palma P, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F. Fontugne J, et al. Among authors: cantaloni c. Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):594-600. doi: 10.1158/1055-9965.EPI-13-1180. Epub 2014 Feb 10. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24515272 Free PMC article.
22 results